New horizons in diabetes mellitus and cardiovascular disease /
| Müşterek Yazar: | |
|---|---|
| Diğer Yazarlar: | , |
| Materyal Türü: | Kitap |
| Dil: | English |
| Baskı/Yayın Bilgisi: |
London :
Current Science,
c1995.
|
| Konular: |
İçindekiler:
- Type II diabetes and its macrovascular complications
- Insulin resistance and hyperinsulinemia: the link betwwen NIDDM, CAD, hypertension and dyslipidemia
- The role of angiotensin-I converting enzyme gene in the pathogenesis of non-insulin-dependent diabetes mellitus
- Glucose recognition and other signalling events in insulin secretion
- The insulin receptor, insulin action and the mechanisms of insulin resistance in diabetes and atherosclerosis
- The immune system and diabetes mellitus
- The impact of diabetes mellitus on public health in Mexico
- The Metabolic Disease Syndrome: lessons to be learned from racial and ethnic diversity
- The coagulation system, diabetes and cardiovascular diseases
- Plasma lipids in diabetes
- Low-density lipoprotein size in patients with NIDDM and the insulin resistance syndrome
- Lipid and lipoprotein advanced glycosylation in diabetic cardiovascular disease
- Oxidative stress and diabetes mellitus
- Cellular and molecular mechanisms in the macroangiopathy of diabetes
- Role of abnormal platelet function in the vascular complicatios of diabetes mellitus
- The nature and consequences of microvascular disease in diabetes mellitus
- Proinsulin and cardiovascular risk
- Is insulin-like growth factor-1 a cardiovascular risk factor? The effects of diabetic autonomic neuropathy on the cardiovascular system
- The pathogenesis of diabetic neuropathy
- UK Prospective Diabetes Study: 3-year update
- Management of hyptertension in the diabetic patient: evolving concepts
- Pathogenesis and management of diabetic nephropathy
- Pancreatic transplantation, implantable insulin pumps, and hybrid artificial pancreas
- Alpha-glucosidase inhibition, a new therapeutic principle in the management of diabetes mellitus
- Treatment of non-insulin-dependent (type II) diabetes with alpha-glucosidase inhibitors.